A dose escalation and phase II study of gemtuzumab ozogamicin (CMA-676; Mylotarg) with high-dose cytarabine for patients with refractory or relapsed acute myeloid leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 18 Jul 2016
At a glance
- Drugs Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2005 New trial record.